On June 14, 2019, Hansoh listed on the Hong Kong Stock Exchange, raising roughly $1 billion in proceeds. The IPO was a resounding success, pricing in what are currently choppy equity market conditions.
Founded in 1995, Hansoh is a leading Chinese pharmaceutical company with an established leadership position in some of the largest and fastest-growing therapeutic areas in China. Hillhouse was the first investor outside the company’s founding family. Prior to its listing, Hansoh was one of the largest privately owned pharmaceutical companies in China. Proceeds from the listing will mainly be used to continue funding R&D programs and adding manufacturing capabilities.